11:32 AM EST - Aeterna Zentaris Inc. : Announced today that the Pediatric Committee of the European Medicines Agency agreed to the Company’s Pediatric Investigation Plan for Macrilen™ and agreed that the Company may defer conducting the PIP until after it files a Marketing Authorization Application, seeking marketing authorization for the use of Macrilen™ for the evaluation of adult growth hormone deficiency. Aeterna Zentaris Inc.
shares T.AEZS are trading up $0.19 at $4.24.
